Humacyte’s (HUMA) “Buy” Rating Reiterated at D. Boral Capital

Humacyte (NASDAQ:HUMA)‘s stock had its “buy” rating restated by D. Boral Capital in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $25.00 price target on the stock. D. Boral Capital’s price objective suggests a potential upside of 340.92% from the stock’s previous close.

A number of other brokerages have also recently weighed in on HUMA. Benchmark reissued a “buy” rating and set a $15.00 price target on shares of Humacyte in a research report on Thursday, October 10th. Cantor Fitzgerald restated an “overweight” rating and issued a $13.00 price target on shares of Humacyte in a report on Friday, September 20th. EF Hutton Acquisition Co. I raised Humacyte to a “strong-buy” rating in a research note on Monday, September 9th. Piper Sandler set a $6.00 price objective on Humacyte and gave the stock a “neutral” rating in a research report on Friday, October 18th. Finally, TD Cowen restated a “buy” rating and set a $10.00 target price on shares of Humacyte in a research report on Friday, October 18th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $13.43.

Humacyte Trading Up 63.9 %

HUMA traded up $2.21 during midday trading on Friday, reaching $5.67. 40,648,918 shares of the company were exchanged, compared to its average volume of 2,546,167. The stock has a market capitalization of $713.62 million, a P/E ratio of -4.23 and a beta of 1.38. Humacyte has a one year low of $2.48 and a one year high of $9.97. The stock’s 50-day simple moving average is $4.85 and its 200 day simple moving average is $5.87. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.10 and a current ratio of 1.10.

Insider Activity at Humacyte

In other news, CEO Laura E. Niklason sold 261,369 shares of the stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $4.40, for a total transaction of $1,150,023.60. Following the completion of the transaction, the chief executive officer now owns 1,730,884 shares in the company, valued at approximately $7,615,889.60. This represents a 13.12 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Brady W. Dougan sold 427,459 shares of Humacyte stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the completion of the transaction, the director now owns 1,992,253 shares of the company’s stock, valued at $8,646,378.02. The trade was a 17.67 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,500,000 shares of company stock worth $6,606,799. 11.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp raised its stake in shares of Humacyte by 62.7% during the second quarter. Bank of New York Mellon Corp now owns 254,013 shares of the company’s stock worth $1,219,000 after acquiring an additional 97,931 shares in the last quarter. Principal Financial Group Inc. bought a new position in shares of Humacyte during the 2nd quarter valued at $83,000. nVerses Capital LLC purchased a new position in Humacyte in the 2nd quarter worth $28,000. Rhumbline Advisers raised its position in Humacyte by 87.8% in the 2nd quarter. Rhumbline Advisers now owns 110,919 shares of the company’s stock worth $532,000 after purchasing an additional 51,858 shares during the period. Finally, Endowment Wealth Management Inc. lifted its stake in Humacyte by 3.1% in the second quarter. Endowment Wealth Management Inc. now owns 100,518 shares of the company’s stock worth $482,000 after purchasing an additional 3,000 shares during the last quarter. Institutional investors own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.